DOI: 10.7759/cureus.39728

Review began 05/18/2023 Review ended 05/25/2023 Published 05/30/2023

© Copyright 2023

Somisetty et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

# Comparing the Efficacy of Intra-articular Platelet-Rich Plasma and Corticosteroid Injections in the Management of Frozen Shoulder: A Randomized Controlled Trial

Tarun Kumar Somisetty <sup>1</sup>, Hariprasad Seenappa <sup>1</sup>, Subhashish Das <sup>2</sup>, Arun H. Shanthappa <sup>1</sup>

1. Orthopedics, Sri Devaraj Urs Medical College, Kolar, IND 2. Pathology, Sri Devaraj Urs Medical College, Kolar, IND

Corresponding author: Hariprasad Seenappa, drhariprasad.ortho@gmail.com

#### **Abstract**

#### Introduction

Periarthritis of the shoulder, or frozen shoulder (FS), is a common, painful, and disabling condition with varied treatment strategies. Intra-articular (IA) corticosteroid (CS) injections are a popular treatment option, but their efficacy is often temporary. Platelet-rich plasma (PRP) has emerged as an alternative therapy for adhesive capsulitis, but the literature on its effectiveness is limited. This study aimed to compare the efficacy of IA PRP and CS injections in managing FS.

#### **Methods**

In this prospective, randomized study, 68 patients who met the inclusion criteria were enrolled and randomized using a computer-generated table into two groups: Group 1 (IA PRP) received 4 ml PRP, and Group 2 (IA CS) received 2 ml (80 mg) of methylprednisolone acetate mixed with 2 ml normal saline (for a total of 4 ml) as a CS injection in the IA area of the shoulder. Outcome measures included pain; shoulder range of motion (ROM); the condensed version of the disabling conditions of the arm, shoulder, and hand (QuickDASH) score; and the shoulder pain and disability index (SPADI) score. Participants were monitored via follow-up for 24 weeks, with pain and function assessed at each evaluation using the visual analog scale (VAS) score, the SPADI score, and the QuickDASH score.

#### Results

The IA PRP injections demonstrated better long-term outcomes than the IA CS injections, significantly improving pain, shoulder ROM, and daily activity performance. After 24 weeks, the mean VAS score in the PRP and methylprednisolone acetate groups was 1.00 (1.0 to 1.0) and 2.00 (2.0 to 2.0), respectively (P<0.001). The mean QuickDASH score was  $41.83 \pm 6.33$  in the PRP group and  $48.76 \pm 5.08$  in the methylprednisolone acetate group (P<0.001). The mean SPADI score was  $53.32 \pm 7.49$  in the PRP group and  $59.24 \pm 5.80$  in the methylprednisolone acetate group (P<0.001), indicating a significant improvement in the PRP group's pain and disability scores after 24 weeks. The rate of complications was similar between the two groups.

#### **Conclusions**

Our findings suggest that IA PRP injections provide better long-term results than IA CS injections for managing FS. Platelet-rich plasma can be used as a treatment modality for better outcomes, particularly when the patient is contraindicated or refuses CS treatment. Further research is needed to evaluate the efficacy of these treatment modalities at different stages of FS and explore the potential benefits of ultrasound-guided injections.

Categories: Pain Management, Orthopedics, Therapeutics

**Keywords:** quickdash, spadi, intraarticular corticosteroid injection, intraarticular platelet-rich plasma injection, frozen shoulder, periarthritis shoulder

## Introduction

Periarthritis of the shoulder, also known as frozen shoulder (FS) or adhesive capsulitis, is characterized by chronic shoulder pain and restricted range of motion (ROM) [1]. There are two subtypes of FS: primary (idiopathic) and secondary. A secondary FS results from an accident, rotator cuff dysfunction, impingement, cardiovascular illness, hemiparesis, or diabetes [2]. The annual incidence of FS in the general population ranges from 3% to 5%, and in individuals with diabetes, it can reach 20% [3].

In modifying a patient's perception of their general health, the burden of shoulder pathologies has been ranked as high as the burden of having congestive heart failure, hypertension, acute myocardial infarction, diabetes mellitus, and/or depression [4]. Previously considered self-limiting, recent literature reveals that

the course of the disease might last as long as 10 years, with up to 40% of patients continuing to suffer from it throughout their lives [5].

Treating a frozen shoulder often involves temporary relief through intra-articular (IA) corticosteroid (CS) injections. A randomized control study has shown that IA CS results in pain relief and improved ROM in patients suffering from FS [6]. However, recent advancements have introduced platelet-rich plasma (PRP) as a promising alternative therapy. Platelet-rich plasma is an autologous blood fraction that is easy to use, quickly prepared, and minimally invasive. It comprises concentrated platelets and growth factors that deliver growth-promoting cytokines and other molecular derivatives to the injury site, promoting healing [7]. In recent studies, IA PRP injections were used as a treatment modality for managing FS, showing improved pain and ROM during long-term follow-up [8].

Therefore, the current randomized controlled study aims to determine the clinical efficacy of IA PRP and IA CS in FS in terms of pain relief and improvement of ROM using the visual analog scale (VAS) score; the shoulder pain and disability index (SPADI) score; and the condensed version of the disabling conditions of the arm, shoulder, and hand (QuickDASH) score.

# **Materials And Methods**

A prospective, randomized, controlled hospital-based observational follow-up study was conducted at the R L Jalappa Hospital and Research Center (Kolar, India), orthopedics department from December 2020 to July 2022. The study was approved by the institutional ethics committee of Sri Devaraj Urs Medical College, Kolar, India (approval no. DMC/KLR/IEC/740/2022-23), and written informed consent was obtained from all participants. Participants were randomly divided into two groups using a computer-generated randomization table. Group 1 (IA PRP) received 4 ml PRP, while Group 2 (IA CS) received 2 ml (80 mg) of methylprednisolone acetate mixed with 2 ml normal saline (for a total of 4 ml) as a CS injection into the shoulder's IA area.

Patients of either sex aged 18 to 75 years with a clinical diagnosis of FS who desired a higher level of activity but could not achieve it even after three months of conservative treatment were included in the study. Patients on antiplatelet, anticoagulant therapy, antitumor or immunosuppressive drugs, uncontrolled diabetes, shoulder instability, immunodeficiency, local skin lesions, or a history of trauma or surgery were excluded from the study. Participants in both groups were assessed at the end of two, four, eight, 12, and 24 weeks following the procedure.

#### Statistical analysis

Data were entered into a Microsoft Excel (Microsoft Corp., Redmond, WA, USA) sheet, and statistical analysis was performed using SPSS Statistics version 24.0 (IBM Corp., Armonk, NY, USA). The descriptive analysis presented the relevant statistics (mean ± SD) for quantitative variables, while frequency and percentage were used for categorical variables. The independent sample t-test was used to determine the mean values of quantitative parameters that were normally distributed among the two study groups. For non-normally distributed quantitative parameters, medians and interquartile ranges were compared between the two study groups using the Mann-Whitney U test. We considered P<0.05 as statistically significant.

#### Results

The mean age was  $58.3\pm8.1$  years in the IA PRP group and  $58.5\pm7.7$  years in the IA CS group, with no statistically significant difference between the two study groups (P=0.9394). In the IA PRP group, 15 participants (44.12%) were male, and 19 (55.88%) were female, while in the IACS group, 20 participants (58.82%) were male, and 14 (41.18%) were female. The difference in sex proportion between the study groups was not statistically significant (P=0.2251). In the IA PRP group, 18 (52.94%) reported right-side involvement, and 16 (47.06%) reported left-side involvement. In the IA CS group, 23 (67.65%) reported right-side involvement, and 11 (32.35%) reported left-side involvement (P=0.2153). There was no statistically significant difference in the proportion of duration (months) between the study groups (P=0.105). In the IA PRP group, 12 participants (35.29%) had diabetes, while 14 (41.18%) had diabetes in the IA CS group. The difference between the two study groups was not statistically significant (P=0.6177). Eight participants (23.53%) had hypertension in the IA PRP group, while two (5.88%) had hypertension in the IA CS group. The difference between the two study groups was not statistically significant (P=0.0832). One participant (2.94%) in the IA CS group, and two participants (5.88%) in the IA PRP group experienced complications, but the difference was not statistically significant (P=1.00, Table 1).

Parameter	Type	Group 1 (IA PRP), n (%)	Group 2 (IA CS), n (%)	P-value
Sex	Male	15 (44.12%)	20 (58.82%)	0.2251
	Female	19 (55.88%)	14 (41.18%)	
Side	Right	18 (52.94%)	23 (67.65%)	0.2153
	Left	16 (47.06%)	11 (32.35%)	
Duration	<6 Months	12 (35.29%)	7 (20.59%)	0.105
	6-12 Months	10 (29.41%)	14 (41.18%)	
	12-18 Months	10 (29.41%)	5 (14.71%)	
	18-24 Months	2 (5.88%)	6 (17.65%)	
	>24 Months	0 (0%)	2 (5.88%)	
Comorbidities	Diabetes	12 (35.29%)	14 (41.18%)	0.6177
	No Diabetes	22 (64.71%)	20 (58.82%)	
	Hypertension	8 (23.53%)	2 (5.88%)	0.0832
	No Hypertension	26 (76.47%)	32 (94.12%)	
Complications	Present	2 (5.88%)	1 (2.94%)	1.000
	Absent	32 (94.12%)	33 (97.06%)	

### TABLE 1: Study population demographic data (n=68), with 34 in each group

IA: Intra-articular, PRP: Platelet-rich plasma, CS: Corticosteroid

The median difference in VAS between the study groups at pre-injection and eight weeks was not statistically significant (P>0.05). However, a significant difference was found in VAS at post-injection, two, four, 12, and 24 weeks (Table 2).

Parameters	Group 1 (IA PRP), n=34, median (IQR)	Group 2 (IA CS), n=34, median (IQR)	Mann-Whitney U-test P-value
Pre-injection (VAS score)	8.50 (8.0 to 9.0)	8.00 (7.0 to 9.0)	0.1439
Post-injection (VAS score)	7.00 (7.0 to 8.0)	6.00 (5.25 to 7.0)	
VAS at 2 weeks	6.00 (6.0 to 7.0)	5.00 (4.25 to 6.0)	
VAS at 4 weeks	5.00 (5.0 to 6.0)	5.00 (4.0 to 5.0)	0.0021
VAS at 8 weeks	4.00 (3.0 to 4.0)	4.00 (3.0 to 4.0)	0.4766
VAS at 12 weeks	2.00 (2.0 to 3.0)	3.00 (2.0 to 3.0)	0.0011
VAS at 24 weeks	1.00 (1.0 to 1.0)	2.00 (2.0 to 2.0)	

#### TABLE 2: VAS scores between the groups over time (n=68)

IA: Intra-articular, PRP: Platelet-rich plasma, CS: Corticosteroid, IQR: Interquartile range, VAS: Visual analog scale

The mean difference between the study groups in QuickDASH at pre-injection, post-injection, two weeks, and four weeks was not statistically significant (P>0.05). However, a significant difference was found in QuickDASH at eight weeks, 12 weeks, and 24 weeks (Figure 1).




# FIGURE 1: : Line chart of QuickDASH score between groups over time (n=68)

Both study groups experienced a progressive decline in QuickDASH scores, while Group 1 (IA PRP) experienced a considerable decline at eight, 12, and 24 weeks.

QuickDASH: Condensed version of the disabling conditions of the arm, shoulder, and hand score; IA: Intraarticular; PRP: Platelet-rich plasma

The mean difference in SPADI between the study groups at pre-injection, post-injection, two weeks, and four weeks was not statistically significant (P>0.05). However, a significant difference was discovered in SPADI at eight weeks, 12 weeks, and 24 weeks (Figure 2).



# FIGURE 2: Line chart of SPADI score between groups over time (N=68)

The SPADI score declined in both groups. But after eight, 12, and 24 weeks, Group 1 (IA PRP) had a significantly lower SPADI score than Group 2 (IA CS).

SPADI: Shoulder pain and disability index, IA: Intra-articular, PRP: Platelet-rich plasma, CS: Corticosteroid

#### **Discussion**

Frozen shoulder is a common, painful, and incapacitating ailment that is self-limiting. It has three clinical phases: (1) the painful freezing phase, lasting 10 to 30 weeks; (2) the adhesive/frozen phase, occurring four

to 12 months after disease onset; and (3) the resolution/thawing phase, developing 12 to 42 months after disease onset. Flexion and abduction movements are more restricted than other shoulder joint movements [9]. Approximately 70% of total FS patients are female, and the dominant arm is more commonly affected than the non-dominant arm [10]. Those who have previously experienced FS have a 5% to 34% probability of developing it in the opposite shoulder at some point. Synchronous bilateral involvement occurs in approximately 14% of patients [11].

Up to 90% of patients with FS benefit greatly from conservative treatment, with the method often used depending on the clinicopathological stage of the condition. Common conservative management options include oral medications like non-steroidal anti-inflammatory drugs (NSAIDs), calcitonin, CS, physical therapy, exercise, IA steroid injections, and hydrodilation. Only a few patients who do not improve with conservative therapy require surgical intervention, such as manipulation under anesthesia or arthroscopic capsular release [12].

The etiology, treatment strategy, and treatment choice for FS remain debated. Although steroid injections are the most popular form of therapy, they provide only temporary pain relief and ROM improvement and are associated with complications [13]. Recently, PRP has gained popularity as an alternative to steroids for treating FS, particularly when patients have rejected or are contraindicated for steroid use. Preliminary evidence suggests that PRP injections are associated with better functional outcomes [14].

According to Lin et al., PRP injection was more effective and longer-lasting than IA CS injection [15]. The researchers attributed the anti-inflammatory and analgesic effects as the factors responsible. Platelet-rich plasma also promotes soft tissue revascularization and increases the local concentration of growth factors to enhance and accelerate recovery [15].

In our study population, FS affected males more frequently than females (ratio 1.06:1). This contrasts with the findings of Upadhyay et al. [14], who reported female predominance and involvement of the non-dominant side compared to the dominant side. Kothari et al. [3] had a similar age range in their study population (mean age  $51.9 \pm 10.1$  years) but found female dominance, and the majority had dominant side involvement (58.9%).

Most of our study population experienced symptoms for six to 12 months, followed by less than six months and 12 to 18 months, indicating that most patients presented in the freezing and frozen stages. The proportion of comorbidities, such as diabetes and hypertension, was insignificant between the groups. Diabetes mellitus (38%) was the most common comorbidity in the study population, followed by hypertension (15%), which is consistent with the findings of Gupta et al. [6].

Our study results align with Buchbinder et al. [16] and Wang et al. [17], who found that steroid injections for FS could be helpful, even if their effects might be transient and not long-lasting. Upadhyay et al. [14] found that PRP injections had a long-term effect on pain relief and improved shoulder function, lasting about 12 weeks.

Aslani et al. [18] also reported similar findings to our study, demonstrating improvements in QuickDASH score, reduction in shoulder pain, and improvement in ROM when assessing the role of PRP in managing FS. Ünlü et al. [19] evaluated the efficacy of IA PRP injection versus normal saline in managing FS and found improvements in SPADI score and reductions in VAS score, similar to our results obtained in the PRP group.

Platelet-rich plasma has chemotactic and mitogenic properties and functions as a growth factor agonist. The combination of large amounts of activated platelets, growth factors, and anti-inflammatory compounds alters the healing cascade and inflammatory pathway, reversing the degenerative process [6,14,20]. Our study found a significant decrease in SPADI scores at all follow-up intervals.

Yoon et al. demonstrated no appreciable changes in the effectiveness of CS at various levels, suggesting a preference for initially using a low dose and tapering off its effects in long-term follow-up [21]. To determine whether PRP can be used for long-term follow-up in managing FS, a major limitation for IA CS, a study assessing PRP in FS found relief of symptoms even after 12 weeks [22]. The rate of complications observed in our study was similar to those reported by Kothari et al. [3], Barman et al. [20], and Upadhyay et al. [14].

Despite the meticulously designed protocol of our study, there are some limitations. All stages of FS were included in the study, so further research is needed to evaluate the efficacy of these treatment modalities in different stages of FS. This prospective randomized study is purely subjective (SPADI score) as no attempts were made to examine the repair using imaging methods like MRI or histopathology assessment. Future research may investigate the role of ultrasound-guided injections in the musculoskeletal system.

#### **Conclusions**

Our study demonstrated that IA PRP injection resulted in better outcomes i.e., decreased pain, improved

shoulder ROM, and increased ability to perform daily activities for patients with FS compared to IA CS injection. Platelet-rich plasma showed better long-term outcomes than CS, suggesting that PRP can be used as a treatment modality in managing FS for better results. We emphasize the emerging importance of PRP in treating chronic musculoskeletal disorders like FS, particularly in situations where the patient refuses or is contraindicated for CS treatment.

#### **Additional Information**

#### **Disclosures**

Human subjects: Consent was obtained or waived by all participants in this study. Institutional Ethics Committee of Sri Devaraj Urs Medical College issued approval DMC/KLR/IEC/740/2022-23. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

#### References

- Akanda BH: Prevalence of frozen shoulder: a cross-cut survey. J Clin Lab Res. 2022, 5: 10.31579/2768-0487/075
- Marx RG, Malizia RW, Kenter K, Wickiewicz TL, Hannafin JA: Intra-articular corticosteroid injection for the treatment of idiopathic adhesive capsulitis of the shoulder. HSS J. 2007, 3:202-207. 10.1007/s11420-007-9044-5
- Kothari SY, Srikumar V, Singh N: Comparative efficacy of platelet-rich plasma injection, corticosteroid injection and ultrasonic therapy in the treatment of periarthritis shoulder. J Clin Diagn Res. 2017, 11:RC15-RC18. 10.7860/JCDR/2017/17060.9895
- Sharma SP, Moe-Nilssen R, Kvåle A, Bærheim A: Predicting outcome in frozen shoulder (shoulder capsulitis) in presence of comorbidity as measured with subjective health complaints and neuroticism. BMC Musculoskelet Disord. 2017. 18:380. 10.1186/s12891-017-1740-9
- Brindisino F, Silvestri E, Gallo C, et al.: Depression and anxiety are associated with worse subjective and functional baseline scores in patients with frozen shoulder contracture syndrome: a systematic review. Arthrosc Sports Med Rehabil. 2022, 4:e1219-e1234. 10.1016/j.asmr.2022.04.001
- Gupta GK, Shekhar S, Haque ZU, et al.: Comparison of the efficacy of platelet-rich plasma (PRP) and local corticosteroid injection in periarthritis shoulder: a prospective, randomized, open, blinded end-point (PROBE) study. Cureus. 2022, 14:10.7759/CUREUS.29253
- 7. Bennell KL, Hunter DJ, Paterson KL: Platelet-rich plasma for the management of hip and knee osteoarthritis. Curr Rheumatol Rep. 2017, 19:24. 10.1007/s11926-017-0652-x
- Mishra A, Harmon K, Woodall J, Vieira A: Sports medicine applications of platelet-rich plasma. Curr Pharm Biotechnol. 2012, 13:1185-1195. 10.2174/138920112800624283
- 9. Dias R, Cutts S, Massoud S: Frozen shoulder. BMJ. 2005, 331:1453-1456. 10.1136/bmj.331.7530.1453
- Neviaser AS, Neviaser RJ: Adhesive capsulitis of the shoulder. J Am Acad Orthop Surg. 2011, 19:536-542.
  10.5435/00124635-201109000-00004
- Malavolta EA, Gracitelli MEC, Pinto G de MR, da Silveira AZF, Assunção JH, Neto AAF: Asian ethnicity: a risk factor for adhesive capsulitis?. Rev Bras Ortop. 2018, 53:602-606. 10.1016/j.rboe.2018.02.004
- 12. Cho CH, Bae KC, Kim DH: Treatment strategy for frozen shoulder. Clin Orthop Surg. 2019, 11:249-257. 10.4055/cjos.2019.11.3.249
- Pandey V, Madi S: Clinical guidelines in the management of frozen shoulder: an update!. Indian J Orthop. 2021, 55:299-309. 10.1007/s43465-021-00351-3
- Upadhyay S, Jorule K, Varma HS, et al.: Ongoing efficacy of platelet-rich plasma vs corticosteroid injection in patients with adhesive capsulitis: a prospective randomized assessor-blind comparative analysis. J Rec Adv Pain. 2020, 6:10-16. 10.5005/jp-journals-10046-0160
- Lin MT, Hsiao MY, Tu YK, Wang TG: Comparative efficacy of intra-articular steroid injection and distension in patients with frozen shoulder: a systematic review and network meta-analysis. Arch Phys Med Rehabil. 2018, 99:1383-1394.e6. 10.1016/j.apmr.2017.08.471
- Buchbinder R, Green S, Youd JM: Corticosteroid injections for shoulder pain. Cochrane Database Syst Rev. 2003, 2003:CD004016. 10.1002/14651858.CD004016
- Wang W, Shi M, Zhou C, Shi Z, Cai X, Lin T, Yan S: Effectiveness of corticosteroid injections in adhesive capsulitis of shoulder: a meta-analysis. Medicine (Baltimore). 2017, 96:e7529. 10.1097/MD.0000000000007529
- Gupta GK, Shekhar S, Haque ZU, Halder S, Manjhi AK, Rai A: Comparison of the efficacy of platelet-rich plasma (prp) and local corticosteroid injection in periarthritis shoulder: a prospective, randomized, open, blinded end-point (probe) study. Cureus. 2022, 14:e29253. 10.7759/cureus.29253
- Ünlü B, Çalış FA, Karapolat H, Üzdü A, Tanıgör G, Kirazlı Y: Efficacy of platelet-rich plasma injections in patients with adhesive capsulitis of the shoulder. Int Orthop. 2021, 45:181-190. 10.1007/s00264-020-04518-
- Barman A, Mukherjee S, Sahoo J, et al.: Single intra-articular platelet-rich plasma versus corticosteroid injections in the treatment of adhesive capsulitis of the shoulder: a cohort study. Am J Phys Med Rehabil. 2019, 98:549-557. 10.1097/PHM.000000000001144
- 21. Yoon SH, Lee HY, Lee HJ, Kwack KS: Optimal dose of intra-articular corticosteroids for adhesive capsulitis: a

randomized, triple-blind, placebo-controlled trial. Am J Sports Med. 2013, 41:1133-1139. 10.1177/0363546513480475

22. Yugandhar S: Role of platelet rich plasma in patients with periarthritis shoulder . Eur J Mol Clin Med. 2022, 9:2404-2414.